The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.
Dr Tarantino on the Potential Significance of SGN-B7H4V in Breast Cancer
December 4th 2023Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.
Watch
Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape
The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Watch
The FDA has granted fast track designation to zotatifin for use in combination with fulvestrant and abemaciclib as second- or third-line therapy for the treatment of patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK4/6 inhibitor.
Read More
In this fourth episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss how to appropriately manage patients with stage IV breast cancer and outline when surgical approaches may be appropriate for this population.
Watch
Educating Community Specialists on Evolving Treatment Landscape
Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.
Watch
Future Outlook for Treating Breast and Lung Cancers
Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.
Watch
Novel Treatment Approaches Under Investigation for HER2+ mBC
November 23rd 2023Joseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.
Watch
Reviewing Best Practices in the Surgical Management of Breast Cancer: Key Advances
November 21st 2023In this third episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss key advancements made in the surgical treatment of patients with breast cancer.
Watch
Future Directions in Gastric Cancer Treatment
Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.
Watch
Treatment Considerations With TROP2-Targeted Therapy
Clinical insights on best practices for treating patients with TROP2-targeted therapy.
Watch
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Read More
Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC
November 16th 2023Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.
Watch
Dr Conlin on Targeting CNS Metastases in the Treatment of Breast Cancer
November 15th 2023Alison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.
Watch